Theorem Clinical Research

Global News

Bayer plans to focus entirely on life science businesses

Thursday, September 18, 2014 01:27 PM

Bayer has announced that it intends, in the future, to focus entirely on its life science businesses—HealthCare and CropScience—and float MaterialScience on the stock market as a separate company. In this way Bayer is positioning itself as a human, animal and plant health company. The supervisory board unanimously has approved the board of management's plans.

More... »


Noxxon Pharma appoints Don Munoz chief financial officer

Thursday, September 18, 2014 01:15 PM

Noxxon Pharma, based in Berlin, Germany, has appointed Don Munoz to the newly created position of chief financial officer. Munoz will strengthen the executive management board and will be based in Noxxon’s new subsidiary office in Boston, Mass.

More... »


Immune Pharmaceuticals initiates phase II clinical trial in ulcerative colitis

Thursday, September 18, 2014 01:10 PM

Immune Pharmaceuticals has initiated the screening of patients for a phase II proof-of-concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

More... »

AstraZeneca, Eli Lilly ink agreement for AZD3293 for Alzheimer’s disease

Wednesday, September 17, 2014 02:28 PM

AstraZeneca and Eli Lilly have inked an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.

More... »

Curie-Cancer, Inventiva partners in epigenetics for cancer

Wednesday, September 17, 2014 02:25 PM

Curie-Cancer, the body responsible for Institut Curie’s industry partnership activities, and Inventiva, a French drug discovery company focusing on therapeutic approaches involving transcription factors and epigenetic targets, have launched the Epicure project, which just has received financial backing from France’s national research agency, the ANR (Agence Nationale pour la Recherche).

More... »

Denovo Biopharma acquires late-stage oncology drug from Eli Lilly

Wednesday, September 17, 2014 02:14 PM

Denovo Biopharma, a San Diego-based, privately held biotechnology company, has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data and information.

More... »

MedGenesis, Pfizer ink agreement for Parkinson's disease

Wednesday, September 17, 2014 02:13 PM

MedGenesis Therapeutix, a Canada-based, privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.

More... »

Endo International seeks to acquire Auxilium Pharmaceuticals for $2.2B

Wednesday, September 17, 2014 02:12 PM

Endo International, a Dublin-based global specialty healthcare company, has delivered an unsolicited proposal to acquire all of the outstanding shares of Chesterbrook, Pa.-based Auxilium Pharmaceuticals for a per share consideration of $28.10, in a cash and stock transaction valued at $2.2 billion.

More... »

International Progressive MS Alliance awards $28.4M in research grants

Tuesday, September 16, 2014 08:00 AM

The International Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries, with the goal of removing barriers to developing treatments for progressive multiple sclerosis (MS). The alliance is a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis that have so far eluded the scientific community.

More... »

Parexel expands Perceptive Partner Program, adds CRF Health and Clinical Ink

Monday, September 15, 2014 12:41 PM

Parexel International, a Massachusetts-based global biopharmaceutical services organization, has announced that clinical technology companies CRF Health, a provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials, and Clinical Ink, a Winston-Salem, N.C.-based eSource solutions company, have joined its Perceptive Partner Program. 

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs